Search research articles
Contact Us
Filters
Showing results (1-10 of 144) with videos related to
Page
of 15
Sort By:
Alimentary Pharmacology & Therapeutics
|
January 20, 2016
Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
February 16, 2016
Letter: ileal bile acid transporter inhibition--is there a potential for drug-drug interaction?
N R Srinivas
Journal of Clinical Pharmacy and Therapeutics
|
February 24, 2010
CYP2C19 genotype-based (R)-warfarin disposition assessment - some views on data analysis
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
May 4, 2016
Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease
N R Srinivas
Drug Research
|
May 5, 2016
Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin
N R Srinivas
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
March 17, 2010
Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives
N R Srinivas
Drug Research
|
December 2, 2015
Stereoselective Tissue Distribution of Ketolorac in Rats - Differential Uptake of Ketolorac Enantiomers in Certain Tissues
N R Srinivas
CPT: Pharmacometrics & Systems Pharmacology
|
November 5, 2015
Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?
N R Srinivas
Drug Research
|
November 22, 2013
Dilemma with matrix effect in bioanalysis--perspectives from bioavailability/bioequivalence studies for product registration?
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
September 6, 2016
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?
N R Srinivas
Page
of 15
Search research articles
Search
Showing results (1-10 of 144) with videos related to
Sort By:
Page
of 15
Alimentary Pharmacology & Therapeutics
|
January 20, 2016
Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
February 16, 2016
Letter: ileal bile acid transporter inhibition--is there a potential for drug-drug interaction?
N R Srinivas
Journal of Clinical Pharmacy and Therapeutics
|
February 24, 2010
CYP2C19 genotype-based (R)-warfarin disposition assessment - some views on data analysis
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
May 4, 2016
Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease
N R Srinivas
Drug Research
|
May 5, 2016
Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin
N R Srinivas
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
March 17, 2010
Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives
N R Srinivas
Drug Research
|
December 2, 2015
Stereoselective Tissue Distribution of Ketolorac in Rats - Differential Uptake of Ketolorac Enantiomers in Certain Tissues
N R Srinivas
CPT: Pharmacometrics & Systems Pharmacology
|
November 5, 2015
Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?
N R Srinivas
Drug Research
|
November 22, 2013
Dilemma with matrix effect in bioanalysis--perspectives from bioavailability/bioequivalence studies for product registration?
N R Srinivas
Alimentary Pharmacology & Therapeutics
|
September 6, 2016
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?
N R Srinivas
Page
of 15